Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Accrued Liabilities
Editas Medicine Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Accrued Liabilities
$43.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
25%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Editas Medicine Inc's Accrued Liabilities?
Accrued Liabilities
43.8m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Accrued Liabilities amounts to 43.8m USD.
What is Editas Medicine Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
37%
Over the last year, the Accrued Liabilities growth was 10%. The average annual Accrued Liabilities growth rates for Editas Medicine Inc have been 25% over the past three years , 37% over the past five years .